Company intelligence / Profile preview

MedTherapy Biotech

Quincy/Boston, Massachusetts, United Statesmedtherapybiotech.com ↗

Ownership: Private
Development stage: Other

Overview

MedTherapy Biotech has developed a proprietary ultra-fast CAR-T platform that reduces manufacturing time from weeks to days and cuts costs by over 70%. Their lead product(s) have shown high response rates (>90%) in early clinical studies. One partnered product has completed Phase 1 trials in the US with plans for Phase 2 trials in India. The company is expanding its pipeline beyond hematologic cancers into solid tumors and autoimmune diseases.

Therapeutic areas: ImmunologyOncology
Modalities: CAR-T cell therapyGene therapyViral vector-based therapyCell therapy
Industry: Biotech

Partnerships

Collaborations with academic institutions including Harvard UniversityGlobal technology development centers/partners in Canada, UK, US, IndiaIndustry partnerships

Beyond the preview

Go deeper on MedTherapy Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MedTherapy Biotech.

Explore the full profile